



Badalabougou, Rue 50, Porte 734, Bamako, Mali
Téléphone: 20 22 11 11 · 20 22 99 99 · glahospital.com

OFFICIAL IMPACT REPORT

2025–2026 Cataract Surgery Campaign

Prepared for ClearVision Global Health, Inc.

201	\$25,850	February 2026	March 1 – July 1, 2026
Surgeries Completed	Funds Received (USD)	Transfer Received	Campaign Period

SUBMITTED BY Golden Life American Hospital Benjamin Baysal, Chief Executive Officer Badalabougou, Rue 50, Porte 734, Bamako, Mali Tel: +223 20 22 11 11 glahospital.com	SUBMITTED TO ClearVision Global Health, Inc. Eren Coban, Founder & Executive Director 17422 Straloch Lane, Richmond, Texas 77407, USA eren@clearvisionglobalhealth.org clearvisionglobalhealth.org
--	---

Report Date: July 10, 2026
Covering Period: September 2025 – July 2026

1. EXECUTIVE SUMMARY

Golden Life American Hospital (the "Hospital") hereby submits this Official Impact Report to ClearVision Global Health, Inc. ("CVGH" or "the Organization") in fulfillment of its reporting obligations under the 2025 Collaboration Protocol signed between the Hospital and Eren Coban personally on January 15–17, 2026.

This report certifies and documents: the receipt of \$25,850 USD raised and transferred by Eren Coban in February 2026; the completion of a dedicated phacoemulsification cataract surgery campaign conducted from March 1 to July 1, 2026; Eren Coban's virtual participation via video conference during the campaign period, March 13 to April 11, 2026; the patient selection process and criteria applied; the clinical outcomes achieved; the initiation of structured post-operative follow-up; and the ongoing research data collection program in support of ClearVision Global Health's longitudinal outcomes research initiative on access to surgical eye care in underserved communities.

Note on organizational structure: At the time the 2025 Collaboration Protocol was signed and funds were transferred, ClearVision Global Health, Inc. did not yet exist as a legal entity. The protocol was signed between Golden Life American Hospital and Eren Coban as an individual. ClearVision Global Health, Inc. was subsequently incorporated in the State of Texas on June 2, 2026. At Eren Coban's request, and in recognition of his role as Founder and Executive Director of the newly formed organization, Golden Life American Hospital is directing this Impact Report to ClearVision Global Health, Inc. as the organizational successor to his individual fundraising initiative. All activities described herein were conducted in full compliance with the terms of the original Protocol and Mali's applicable regulations.

2. PARTNERSHIP BACKGROUND

Beginning in September 2025, Eren Coban — a pre-medical student based in Richmond, Texas, with a documented history of independent fundraising for cataract surgery initiatives in Africa — reached out to Golden Life American Hospital to propose a structured, supervised surgical partnership for underserved patients in Mali. At this time, Eren Coban was acting entirely as an individual, not as a representative of any registered organization.

Following eight documented email exchanges over approximately four months and three virtual meetings, the Parties signed a formal Collaboration Protocol on January 15–17, 2026, between Golden Life American Hospital and Eren Coban personally. Under this Protocol, Eren Coban committed to fundraising and transferring funds to the Hospital, and the Hospital committed to organizing a dedicated cataract surgery campaign for underserved patients, with Eren Coban participating remotely via video conference during the patient selection and surgical phases.

Eren Coban transferred \$25,850 in fundraising proceeds to the Hospital in February 2026. He participated remotely via scheduled video conferences during March–April 2026, where he joined supervised patient selection discussions as a non-voting observer on the Hospital's evaluation committee, reviewed documentation and recorded briefings on surgical procedures, and contributed to clinical team discussions on outcomes and data collection.

The surgical campaign was conducted by the Hospital from March 1 to July 1, 2026. While the campaign was underway, Eren Coban incorporated ClearVision Global Health, Inc. as a registered nonprofit in the State of Texas (File No. 806631082, Certificate of Formation issued June 2, 2026). A Long-Term Collaboration Protocol between ClearVision Global Health, Inc. and Golden Life American Hospital was subsequently signed on June 12, 2026, formalizing the institutional partnership going forward.

Following the conclusion of the surgical campaign and the formal incorporation of ClearVision Global Health, Inc., Eren Coban requested that the Hospital address and submit this Impact Report to ClearVision Global Health, Inc. as the organizational successor to his individual initiative. Golden Life American Hospital hereby complies with that request and submits this report accordingly.

3. FINANCIAL CERTIFICATION

3.1 Funds Received

The Hospital hereby certifies receipt of the following funds from Eren Coban, transferred from personal fundraising proceeds raised by Eren Coban as an individual prior to the incorporation of ClearVision Global Health, Inc.:

Transfer Date	Amount (USD)	Transfer Method	Designated Purpose
February 2026	\$25,850.00	Wire Transfer	2026 Cataract Surgery Campaign — Mali
TOTAL	\$25,850.00		Fully applied to surgical purposes

3.2 Fund Application — Expenditure Breakdown

Expenditure Category	Amount (USD)	% of Total
Patient pre-selection and screening activities — community outreach, application processing, eligibility interviews, biometry measurements, and logistical coordination across 5 districts	\$3,850	14.9%

Consumables and surgical supplies — foldable intraocular lenses (IOLs) for all 201 cases, viscoelastic agents, complete sterile surgical kits (drapes, gloves, masks, gowns, blades), peri-operative pharmaceuticals (antibiotics, corticosteroids, NSAIDs, dilating drops, anesthetics), irrigation/aspiration fluids, balanced salt solution, sutures, and additional disposables for 201 procedures. Surgical infrastructure, instrumentation, and the established in-hospital team were provided by the Hospital consistent with its standard humanitarian cataract program model.	\$20,600	79.7%
Contingency, administration, documentation, local permits, and post-operative medication support	\$1,400	5.4%
TOTAL	\$25,850.00	100%

All funds were applied exclusively to direct campaign costs with no overhead or administrative markup retained by the Hospital. The original Protocol budget was prepared on the assumption that all equipment would be procured specifically for this campaign, with an estimated yield of approximately 85 surgeries at ~\$304 per patient. In practice, the Hospital conducted the campaign using its existing in-hospital surgical infrastructure and established humanitarian care team, eliminating separate equipment procurement and external team deployment costs. All savings were redirected to patient care consumables and IOLs, enabling the campaign to serve 201 patients at an effective all-inclusive cost of approximately \$128.61 per patient ($\$25,850 \div 201$) — consistent with established benchmarks for hospital-based phacoemulsification programs in comparable West African settings (typical range: \$100–\$150 USD per patient). All funds were fully expended for surgical purposes. A full itemized financial statement will be provided to ClearVision Global Health, Inc. by August 1, 2026.

4. PATIENT SELECTION PROCESS

4.1 Community Outreach and Applications

Patient recruitment commenced in March 2026 through outreach activities across multiple districts including announcements at local health centers, community radio broadcasts in French and Bambara, mosque announcements, and coordination with regional health workers. Applications were received from five districts across Mali.

4.2 Selection Committee and Criteria

The Hospital convened a formal Patient Evaluation Committee comprising two qualified ophthalmologists, one senior clinical nurse, and one administrative coordinator. Eren Coban participated as a non-voting observer on the evaluation committee during his scheduled virtual participation in March–April 2026, consistent with the terms of the Protocol. At the time of his participation, ClearVision Global Health, Inc. had not yet been incorporated; Eren Coban participated in his individual capacity as the fundraiser and Protocol signatory. All clinical decisions remained exclusively with the Hospital's medical team. The following criteria were applied:

- Confirmed cataract diagnosis with clinically significant visual impairment
- Visual acuity at or below 6/60 in the affected eye, qualifying for surgical intervention
- Demonstrated financial need — inability to access or afford surgical care through existing channels
- Medical clearance confirming no contraindications for phacoemulsification surgery
- Geographic accessibility and confirmed ability to attend pre-operative and post-operative appointments
- Written informed consent obtained from patient or legal guardian

4.3 Selection Outcomes

Metric	Result
Total applications received	347
Patients invited for clinical screening	289
Patients selected and confirmed for surgery	201
Patients declined — medical contraindication	48 (16.6%)
Patients declined — logistical or scheduling constraints	40 (13.8%)
Age range of selected patients	34 – 79 years (median age: 58)
Gender breakdown	118 female (58.7%) · 83 male (41.3%)
Geographic districts represented	Bamako, Koulikoro, Kati, Ségou, Bougouni
Bilateral cataract cases (both eyes affected)	87 patients (43.3%) — one eye treated per protocol
Average duration of visual impairment prior to surgery	3.2 years

5. SURGICAL CAMPAIGN — COMPLETION REPORT

5.1 Campaign Structure

The campaign was structured across four phases:

- Phase 1 — March 1–14, 2026: Comprehensive patient screening, eligibility confirmation, pre-operative counseling, biometry measurements, and logistical preparation — identifying and prioritizing cases across 5 districts.
- Phase 2 — March 15 to May 31, 2026: Peak surgical phase — approximately 18–22 procedures per week across 11 weeks, allowing thorough intra-operative monitoring, immediate post-operative care, and team rest periods. Eren Coban participated remotely via video conference from March 13 to April 11, 2026 during this phase, consistent with the Protocol.

- Phase 3 — June 1 – July 1, 2026: Final surgical cases, intensive post-operative follow-up, visual acuity assessments, medication management, complication screening, and patient education on long-term care.
- Ongoing post-campaign — continued post-operative follow-up monitoring at 1-month, 3-month, and 6-month intervals from each patient's surgery date, with data collection supporting the longitudinal outcomes research program.

5.2 Surgical Outcomes

Metric	Result
Total surgeries completed	201
Surgical procedure	Phacoemulsification with foldable IOL implantation
Campaign period	March 1 – July 1, 2026
Surgeries without intraoperative complications	196 (97.5%)
Minor intraoperative complications — all resolved	5 (2.5%) — posterior capsule opacity; managed intraoperatively with no adverse outcomes
Patients with confirmed visual improvement at day 1 post-op	197 (98.0%)
Patients requiring additional post-op intervention	4 (2.0%) — minor medication adjustment for inflammation; all resolved
Average post-op visual acuity (day 7)	6/12 or better in 193 patients (96.0%)
Patient satisfaction — immediate post-op survey	197 rated experience as positive or very positive (98.0%)
Average per-patient total cost	\$128.61 USD (total \$25,850 ÷ 201 patients)

5.3 Post-Operative Follow-Up Schedule

All 201 patients are enrolled in the Hospital's post-operative monitoring program. Follow-up assessments are scheduled at the intervals below from each patient's individual surgery date:

Follow-Up	Assessment Content	Target Completion
1-month	Visual acuity, IOP check, medication review, complication screening	July – August 2026
3-month	Functional vision assessment, quality-of-life evaluation, research survey	September – October 2026
6-month	Final clinical outcome, long-term acuity, research data finalization	November – December 2026

6. RESEARCH PROGRAM

6.1 Overview and Purpose

ClearVision Global Health, Inc. is conducting a longitudinal outcomes research program alongside this surgical campaign. The research is grounded in a central question that directly underpins the Organization's fundraising mission: what are the structural, social, economic, and informational barriers that prevent underserved individuals from accessing available surgical eye care — and how can community-based fundraising, donor engagement, and structured outreach programs provide a sustainable solution?

The research examines the full arc of the patient experience — from the conditions that caused them to go without treatment for years, through the surgical intervention itself, to the individual and social transformation that follows restored vision. It also investigates the role of donor behavior, public awareness, and community education in enabling access to care. The findings are intended to contribute to the global health evidence base on sustainable, community-funded surgical access programs, with the goal of peer-reviewed publication in journals such as PLOS ONE, BMC Ophthalmology, or The Lancet Global Health.

The research program covers four interconnected domains:

- Access barriers — identifying the geographic, financial, cultural, and informational obstacles that prevent patients from reaching available surgical care, including how long patients lived with treatable blindness and what ultimately enabled them to access the program
- Donor behavior and community fundraising — examining what motivates donors to support surgical access programs, how awareness and education drive giving, and what program transparency features build sustained donor trust
- Patient and community impact — tracking individual quality-of-life improvements following surgery through structured pre- and post-operative surveys, including functional independence, occupational recovery, economic participation, and social reintegration
- Program sustainability — analyzing what combination of community outreach, selection criteria, fund management, and outcome documentation enables a grassroots nonprofit to deliver high-quality surgical care efficiently and accountably in a low-resource setting

6.2 Ethics and Patient Consent

All research participation is entirely voluntary and conducted with full informed consent. Each participating patient was individually approached by a designated Hospital research coordinator and invited to participate in structured surveys and interviews in addition to their standard clinical assessments. Consent was obtained in writing in each patient's preferred language — French or Bambara. All data is collected, stored, and shared in full compliance with Mali's national health regulations and data anonymization

standards consistent with the Declaration of Helsinki. No patient names or personally identifying information will be shared with or published by ClearVision Global Health, Inc. without explicit written consent obtained separately for that specific purpose.

6.3 Research Participation

Research Metric	Status
Patients approached for research participation	201 (100%)
Patients providing written informed consent	183 (91.0%)
Pre-operative survey and interview data collected	183 patients (100% of consenting)
Post-operative day-7 data collection complete	181 patients (98.9%)
1-month follow-up data collection	In progress — target August 2026
3-month and 6-month follow-up	Scheduled per patient surgery date

6.4 Data Elements Collected and to Be Delivered

The following research data elements are being collected and will be compiled into a structured, de-identified Research Data Package for delivery to ClearVision Global Health, Inc. by September 1, 2026:

- Pre-operative access barrier interviews: how long the patient lived with cataracts before this program, prior attempts to access care, financial and geographic obstacles encountered, how the patient learned about the program, and what motivated them to apply
- Community awareness and outreach data: which outreach channels reached the most patients, community knowledge gaps regarding cataract surgery availability, and the role of trusted community figures in patient referral
- Patient demographic and socioeconomic data: age, gender, district of origin, primary occupation, household income bracket, and literacy level — de-identified
- Pre-operative clinical data: visual acuity (Snellen), diagnosis classification, lens opacity grading, and biometry measurements
- Intraoperative data: procedure notes, IOL specifications, complications noted, and surgical duration
- Post-operative clinical data at day 1, day 7, 1-month, 3-month, and 6-month intervals: best-corrected visual acuity, IOP, complication status, and medication compliance
- Post-operative quality-of-life surveys: self-reported changes in daily functional independence, occupational activity, household economic contribution, social participation, and emotional wellbeing following restored vision
- Donor and fundraising data provided by ClearVision: donor motivation surveys, giving patterns, impact report engagement, and campaign performance — to be integrated with patient outcome data in the final research analysis

6.5 Research Data Delivery Timeline

Milestone	Target Date
1-month follow-up data collection complete	August 15, 2026
Initial Research Data Package delivered to CVGH	September 1, 2026
3-month follow-up data collection complete	October 31, 2026
6-month follow-up data collection complete	December 31, 2026
Final Research Data Package delivered to CVGH	January 15, 2027

7. TRANSPARENCY AND PUBLIC REPORTING

Golden Life American Hospital supports ClearVision Global Health, Inc.'s commitment to full public transparency with its donors and the public. The Hospital confirms that the following may be published by the Organization on its website at clearvisionglobalhealth.org and in its donor communications:

- Total funds received and confirmation all funds were applied to approved surgical purposes
- Total surgeries completed (201) and campaign period (March 1 – July 1, 2026)
- Patient selection criteria and general process description
- Aggregate surgical outcome data and impact statistics as presented in this report
- This Impact Report in full as a publicly available signed document

No patient names, photographs, or personally identifying information will be published without individual written consent obtained separately for that specific purpose. All published data will be presented in aggregate or fully de-identified form.

8. CERTIFICATION OF PARTNERSHIP, FUNDS, AND SURGERIES



Golden Life American Hospital hereby formally certifies the following on behalf of the Hospital and its authorized leadership:

✓	The Hospital received \$25,850 USD from Eren Coban in February 2026, representing personal fundraising proceeds raised by Eren Coban as an individual, designated exclusively for the 2026 Cataract Surgery Campaign.
✓	At the time of the original Protocol signing (January 2026) and fund transfer (February 2026), ClearVision Global Health, Inc. did not yet exist. The Protocol was signed between Golden Life American Hospital and Eren Coban personally. ClearVision Global Health, Inc. was incorporated on June 2, 2026.
✓	All \$25,850 USD was applied exclusively to approved surgical purposes as detailed in Section 3. No funds were used for unapproved purposes or general Hospital operations.

✓	197 of 201 patients (98.0%) showed confirmed visual improvement at the first post-operative assessment. 196 surgeries (97.5%) were completed without intraoperative complications.
✓	All 201 patients are enrolled in the post-operative monitoring program with follow-up scheduled at 1, 3, and 6 months from each individual surgery date.
✓	183 patients (91.0%) consented to research participation. The complete Research Data Package will be delivered to ClearVision Global Health, Inc. by September 1, 2026.
✓	This report is directed to ClearVision Global Health, Inc. at the request of Eren Coban, as the organizational successor to his individual fundraising initiative, following its incorporation on June 2, 2026.
✓	This report is true, accurate, and complete to the best of the Hospital's knowledge, and is submitted in good faith fulfillment of the Hospital's obligations under the original Protocol.

SIGNATURES AND CERTIFICATION

By signing below, the authorized representatives of Golden Life American Hospital certify that this Impact Report is a true and accurate record of all activities conducted under the 2025–2026 Collaboration Protocol signed with Eren Coban, that all funds were received from Eren Coban personally and applied as stated herein, and that all 201 surgeries described were completed as reported. This report is directed to ClearVision Global Health, Inc. at the request of Eren Coban following its incorporation as a registered nonprofit in June 2026. ClearVision Global Health, Inc. acknowledges receipt of this report and its intent to publish it publicly at clearvisionglobalhealth.org.

FOR GOLDEN LIFE AMERICAN HOSPITAL Signature:  Name: Benjamin Baysal Title: Chief Executive Officer Date: July 1, 2026 Hospital Official Stamp / Seal:	ACKNOWLEDGED BY CLEARVISION GLOBAL HEALTH, INC. Signature:  Name: Eren Coban Title: Founder & Executive Director Date: July 2026 Email: eren@clearvisionglobalhealth.org Web: clearvisionglobalhealth.org
---	--

Hospital Official Stamp / Seal:

Email: eren@clearvisionglobalhealth.org
Web: clearvisionglobalhealth.org

This document constitutes an official certification of partnership activities, funds received, and surgeries completed.

Upon signature by both Parties, this report will be published publicly at clearvisionglobalhealth.org.

Golden Life American Hospital · Bamako, Mali · glahospital.com